Literature DB >> 28547246

Indications for Opioid Antagonists.

O J Michael Coppes1, Christine N Sang2,3.   

Abstract

PURPOSE OF REVIEW: As opioids have become more common in clinical practice for the treatment of both acute and chronic pain, so too has the need for a deeper understanding of the clinical applications of opioid antagonists. The purpose of this review is to present both the longstanding and potential new indications for the use of drugs that block the effects of opioid receptors. RECENT
FINDINGS: There is a growing body of data demonstrating the modulation of pain by opioid antagonists. Additional clinical studies that show their direct antinociceptive effects and/or enhancement of the analgesic potency of opioid agonists are warranted. We briefly discuss the well-established role that these agents play in the reversal of life-threatening opioid toxicity and explore both existing and expanding clinical applications, including their apparent paradox that they may themselves be associated with analgesia.

Entities:  

Keywords:  Naloxone; Naltrexone; Opioid antagonists; Opioids; Pain management

Mesh:

Substances:

Year:  2017        PMID: 28547246     DOI: 10.1007/s11916-017-0630-z

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  51 in total

Review 1.  The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.

Authors:  Helen M Pettinati; Charles P O'Brien; Amanda R Rabinowitz; Shoshana P Wortman; David W Oslin; Kyle M Kampman; Charles A Dackis
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

2.  No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia.

Authors:  C Stein; M Pflüger; A Yassouridis; J Hoelzl; K Lehrberger; C Welte; A H Hassan
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract.

Authors:  D Bagnol; A Mansour; H Akil; S J Watson
Journal:  Neuroscience       Date:  1997-11       Impact factor: 3.590

4.  Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.

Authors:  Helen M Pettinati; Bernard L Silverman; John J Battisti; Robert Forman; Edward Schweizer; David R Gastfriend
Journal:  Alcohol Clin Exp Res       Date:  2011-05-16       Impact factor: 3.455

Review 5.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015

Review 6.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

7.  Randomised crossover trial of naltrexone in uraemic pruritus.

Authors:  G Peer; S Kivity; O Agami; E Fireman; D Silverberg; M Blum; A laina
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

8.  A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.

Authors:  Jon E Grant; Suck Won Kim; Brian L Odlaug
Journal:  Biol Psychiatry       Date:  2009-02-12       Impact factor: 13.382

9.  Opiates and the gastrointestinal tract.

Authors:  S J Konturek
Journal:  Am J Gastroenterol       Date:  1980-09       Impact factor: 10.864

Review 10.  Systematic review and meta-analysis of opioid antagonists for smoking cessation.

Authors:  Sean P David; Isabella M Chu; Tim Lancaster; Lindsay F Stead; A Eden Evins; Judith J Prochaska
Journal:  BMJ Open       Date:  2014-03-14       Impact factor: 2.692

View more
  1 in total

1.  Methadone as a "Tumor Theralgesic" against Cancer.

Authors:  Marta Michalska; Arndt Katzenwadel; Philipp Wolf
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.